Phase 1 Hepatitis B Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are over 18 years old
- People who have been diagnosed with chronic hepatitis B infection (meaning a positive hepatitis B test result for at least 6 months), without also having HIV, hepatitis C, or hepatitis D
- People who have been taking antiviral medication for hepatitis B and whose hepatitis B virus levels in the blood have been very low (below 100 IU/ml) for at least 12 months
- People who are able and willing to attend all scheduled visits, follow the vaccination plan, and complete all required tests and study procedures
- People who a doctor has determined to be in good general health based on their medical history and a physical examination
Who may not be able to join:
- People who are pregnant or breastfeeding
- People who have taken strong immune-suppressing or immune-modifying medicines for more than 14 days in total within the past 6 months (including certain steroid medicines at higher doses), or who have received a specific type of immune-suppressing treatment called anti-CD20 therapy within the past 12 months
- People who have recently received certain vaccines or who plan to receive non-study vaccines close to the time of study vaccinations (specific timeframes apply — confirm with trial site)
- People who have received blood products such as transfusions within the 3 months before joining the trial
- People who have taken part in another clinical trial involving an experimental treatment or device within the past 30 days
- People who have a known allergy to hepatitis B vaccines or yeast-based vaccines
- People whose blood test results at the time of screening show certain signs of liver stress, specifically liver enzyme levels (ALT) more than 3 times the normal upper limit, or elevated bilirubin levels above a certain threshold
- People who are acutely unwell or have a fever (38.0°C/100.4°F or above) within 72 hours before or at the time of receiving the study vaccine
- People who have any ongoing, sudden, or unstable health conditions that the investigating doctor considers a reason not to participate
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lydia Tang, MBChB, University of Maryland, Baltimore
Phone: (410) 706-6567
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety and reactogenicity of the Hepatitis B Virus Surface Antigen, Recombinant (HEPLISAV-B; Dynavax Technologies Corporation) Vaccine in patients with chronic hepatitis B; Occurence of unsolicited adverse events; Medically Attended Adverse Events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.